Coagulopathy Reversal in Intracerebral Haemorrhage

Overview

Journal Stroke Vasc Neurol

Specialty Cardiology & Vascular Diseases

Date 2020 May 16

PMID 32411405

Citations 5

Authors

Alexander Jacob Sweidan

Navneet Kaur Singh

Joseph Luke Conovaloff

Matthew Bower

Leonid I Groysman

Mohammad Shafie

Wengui Yu

Affiliations

Soon will be listed here.

Abstract

As intracerebral hemorrahge becomes more frequent as a result of an aging population with greater comorbidities, rapid identification and reversal of precipitators becomes increasingly paramount. The aformentioned population will ever more likely be on some form of anticoagulant therapy. Understanding the mechanisms of these agents and means by which to reverse them early on is critical in managing the acute intracerebral hemorrhage.

Citing Articles

Specific Reversal Agents for Direct Oral Anticoagulants in Acute Stroke.

Frol S, Oblak J, Sabovic M, van Zwam W, Ntaios G, Lovblad K Clin Appl Thromb Hemost. 2024; 30:10760296241279545.

PMID: 39183537 PMC: 11348480. DOI: 10.1177/10760296241279545.

Reversal and resumption of anticoagulants in patients with anticoagulant-associated intracerebral hemorrhage.

Yang J, Jing J, Chen S, Liu X, Wang J, Pan C Eur J Med Res. 2024; 29(1):252.

PMID: 38659079 PMC: 11044346. DOI: 10.1186/s40001-024-01816-5.

Andexanet Alfa to Reverse the Effect of Factor Xa Inhibitors in Intracranial Hemorrhage.

Frol S, Oblak J, Sabovic M, Kermer P CNS Drugs. 2023; 37(6):477-487.

PMID: 37133623 DOI: 10.1007/s40263-023-01006-7.

Intraparenchymal Hematoma With Significant Mass Effect Treated With Factor Eight Inhibitor Bypass Activity.

Prasad S, Colon Figueroa P, Stead T, Mangal R, Ganti L Cureus. 2022; 14(11):e31385.

PMID: 36514613 PMC: 9741993. DOI: 10.7759/cureus.31385.

Clinical and Imaging Characteristics in Patients with SARS-CoV-2 Infection and Acute Intracranial Hemorrhage.

Nawabi J, Morotti A, Wildgruber M, Boulouis G, Kraehling H, Schlunk F J Clin Med. 2020; 9(8).

PMID: 32781623 PMC: 7464657. DOI: 10.3390/jcm9082543.

References

Sarode R, Milling Jr T, Refaai M, Mangione A, Schneider A, Durn B . Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013; 128(11):1234-43. PMC: 6701181. DOI: 10.1161/CIRCULATIONAHA.113.002283. View

Coleman C, Peacock W, Bunz T, Alberts M . Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack. Stroke. 2017; 48(8):2142-2149. DOI: 10.1161/STROKEAHA.117.017474. View

Perzborn E, Heitmeier S, Laux V, Buchmuller A . Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thromb Res. 2014; 133(4):671-81. DOI: 10.1016/j.thromres.2014.01.017. View

Granger C, Alexander J, McMurray J, Lopes R, Hylek E, Hanna M . Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11):981-92. DOI: 10.1056/NEJMoa1107039. View

le Roux P, Pollack Jr C, Milan M, Schaefer A . Race against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage. J Neurosurg. 2014; 121 Suppl:1-20. DOI: 10.3171/2014.8.paradigm. View

Zahir H, Brown K, Vandell A, Desai M, Maa J, Dishy V . Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation. 2014; 131(1):82-90. DOI: 10.1161/CIRCULATIONAHA.114.013445. View

Stangier J . Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008; 47(5):285-95. DOI: 10.2165/00003088-200847050-00001. View

Frontera J, Gordon E, Zach V, Jovine M, Uchino K, Hussain M . Reversal of coagulopathy using prothrombin complex concentrates is associated with improved outcome compared to fresh frozen plasma in warfarin-associated intracranial hemorrhage. Neurocrit Care. 2014; 21(3):397-406. DOI: 10.1007/s12028-014-9972-0. View

Connolly S, Milling Jr T, Eikelboom J, Gibson C, Curnutte J, Gold A . Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2016; 375(12):1131-41. PMC: 5568772. DOI: 10.1056/NEJMoa1607887. View

10.

Patel M, Mahaffey K, Garg J, Pan G, Singer D, Hacke W . Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883-91. DOI: 10.1056/NEJMoa1009638. View

11.

Connolly S, Ezekowitz M, Yusuf S, Eikelboom J, Oldgren J, Parekh A . Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12):1139-51. DOI: 10.1056/NEJMoa0905561. View

12.

Lubetsky A, Hoffman R, Zimlichman R, Eldor A, Zvi J, Kostenko V . Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation. Thromb Res. 2004; 113(6):371-8. DOI: 10.1016/j.thromres.2004.04.004. View

13.

Kurogi R, Nishimura K, Nakai M, Kada A, Kamitani S, Nakagawara J . Comparing intracerebral hemorrhages associated with direct oral anticoagulants or warfarin. Neurology. 2018; 90(13):e1143-e1149. PMC: 5880631. DOI: 10.1212/WNL.0000000000005207. View

14.

Gelosa P, Castiglioni L, Tenconi M, Baldessin L, Racagni G, Corsini A . Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). Pharmacol Res. 2018; 135:60-79. DOI: 10.1016/j.phrs.2018.07.016. View

15.

Chapman S, Irwin E, Beal A, Kulinski N, Hutson K, Thorson M . Prothrombin complex concentrate versus standard therapies for INR reversal in trauma patients receiving warfarin. Ann Pharmacother. 2011; 45(7-8):869-75. DOI: 10.1345/aph.1P605. View

16.

Majeed A, Agren A, Holmstrom M, Bruzelius M, Chaireti R, Odeberg J . Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood. 2017; 130(15):1706-1712. DOI: 10.1182/blood-2017-05-782060. View

17.

Kohsaka S, Katada J, Saito K, Terayama Y . Safety and effectiveness of apixaban in comparison to warfarin in patients with nonvalvular atrial fibrillation: a propensity-matched analysis from Japanese administrative claims data. Curr Med Res Opin. 2018; 34(9):1627-1634. DOI: 10.1080/03007995.2018.1478282. View

18.

Woo C, Patel N, Conell C, Rao V, Faigeles B, Patel M . Rapid Warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. World Neurosurg. 2012; 81(1):110-5. DOI: 10.1016/j.wneu.2012.12.002. View

19.

Whitlon D, Sadowski J, Suttie J . Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry. 1978; 17(8):1371-7. DOI: 10.1021/bi00601a003. View

20.

Davis S, Broderick J, Hennerici M, Brun N, Diringer M, Mayer S . Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology. 2006; 66(8):1175-81. DOI: 10.1212/01.wnl.0000208408.98482.99. View